Tumor-specific and germ-line variations of DNA significantly contribute to tumor growth and its ability to develop resistance. Among several mechanisms that cause resistance to cancer treatment, the genotype of certain growth factors, like epidermal growth factor receptor (EGFR), is critical. EGFR signals requests for proliferation and survival toward the nucleus of the cancer cell. Several polymorphic DNA sequences ofEGFRand the mutational status of the Kirsten-Ras (KRAS) gene appear to be determinants of response to new drugs that inhibit EGFR. We describe the correlation between theEGFRgenotype, including theKRASmutation, and the consequences of the resulting genotype for anti-EGFR therapy in colorectal cancer.
